cancer therapeutics-related cardiac dysfunction(English)

• defined as a ≥10% absolute decline in LVEF from baseline to a value <50% (or 53%) with or without HF symptoms. More recently, a decline in global longitudinal strain and elevations of cardiac biomarkers have additionally been incorporated into the diagnosis of asymptomatic CTRCD
• EF, HF, ACC, ACHD, ADT, AF, AIC, ATTR, BP, BPA, BRAF, BTK, BTKi, CTR-CVT, CAC, CAD, CAR-T, CCT, CHD, CIED, CLL, CMR, CRS, CTEPH, cTn, cTnI, CTR-RVT, ECG, EGFR, FAC, FWLS, GLS, GnRH, HbA1C, HSCT, HER2, ICI, IE, IHD, IMID, IVC, LAVI, LVEF, MEK, MM, MPI, NBTE, NET, NT-proBNP, PAH, PE, PEA, PI, RAVI, RH, RHC, RHF, RVEDV, RVEF, RVESV, RVLS, RVOT, SCT, TAPSE, TIL, TKI, TRV, TTE, VEGF, VEGFi, VTE
• Cardiology, Oncology, Ratio-based metric, Diagnostics, Prognosis
• https://doi.org…3/ehjci/jeaa288
• http://dx.doi.o…cho.2014.07.012
• https://doi.org…cao.2024.07.017
• https://doi.org….1002/ejhf.3412
• https://doi.org…000000000001174
• https://doi.org…cao.2026.01.006